First Horizon Corp Increases Stock Holdings in Pfizer Inc. $PFE

Key Points

• First Horizon Corp increased its Pfizer stake by 59.6% in the first quarter, buying 122,904 additional shares and bringing its total holding to 329,278 shares worth about $9.25 million.
• Pfizer’s stock remains a mixed picture on Wall Street: the consensus rating is “Hold” with an average target price of $28.56, reflecting cautious analyst sentiment despite some bullish views.
• The company recently beat earnings and revenue estimates for the quarter and reaffirmed its dividend appeal, with a 7.1% yield and a quarterly payout of $0.43 per share.

First Horizon Corp grew its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 59.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 329,278 shares of the biopharmaceutical company's stock after purchasing an additional 122,904 shares during the period. First Horizon Corp's holdings in Pfizer were worth $9,246,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Evolution Wealth Management Inc. increased its stake in Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 566 shares during the period. Horizon Financial Services LLC boosted its holdings in shares of Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. purchased a new position in Pfizer during the fourth quarter worth about $26,000. YANKCOM Partnership purchased a new position in Pfizer during the fourth quarter worth about $28,000. Finally, HFM Investment Advisors LLC lifted its position in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 427 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Wolfe Research restated an "underperform" rating and issued a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. HSBC cut shares of Pfizer from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $32.00 to $28.00 in a research note on Monday. Citigroup boosted their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 29th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $27.00 price target on shares of Pfizer in a report on Monday. Finally, CICC Research started coverage on shares of Pfizer in a report on Thursday, April 16th. They set an "outperform" rating and a $33.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Pfizer currently has an average rating of "Hold" and an average target price of $28.56.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer shares benefited as AstraZeneca’s failed Phase 3 trial in a rare heart disease pushed investors toward rival drugmakers, including PFE. Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump
• Positive Sentiment: Pfizer’s oncology franchise got some attention after reports suggesting recent FDA action on IBRANCE could improve the investment case for the company’s cancer portfolio. Did FDA’s IBRANCE Maintenance Approval Just Shift Pfizer’s (PFE) Oncology-Focused Investment Narrative?
• Positive Sentiment: Pfizer also highlighted ongoing pipeline work, including a Phase 1 bioavailability study and its MUST multiple myeloma study, reinforcing the company’s longer-term R&D pipeline narrative. Pfizer Refines Early-Stage Drug Formulations With New Phase 1 Bioavailability Study Pfizer’s MUST Study Offers Fresh Insight Into Tough‑to‑Treat Multiple Myeloma
• Neutral Sentiment: J.P. Morgan lowered its price target on Pfizer and kept a Neutral rating, which signals continued caution even though the firm still sees some upside from current levels. Pfizer (PFE) Receives a Hold from J.P. Morgan
• Neutral Sentiment: Additional headlines around Pfizer’s dividend appeal, valuation, and analyst commentary are likely reinforcing investor debate, but they do not point to a major fundamental shift by themselves. Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: Jim Cramer declined to recommend Pfizer despite its high dividend yield, reflecting ongoing skepticism about the stock’s near-term appeal. ‘It Kills Me to Say That’: Cramer Won’t Recommend Pfizer, Even With Its 7% Dividend

Pfizer Stock Performance

Pfizer stock opened at $24.22 on Friday. The stock's 50 day moving average price is $25.41 and its 200 day moving average price is $26.20. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The firm has a market capitalization of $138.02 billion, a PE ratio of 18.49 and a beta of 0.35.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business's revenue was up 5.4% on a year-over-year basis. During the same period last year, the business earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. The ex-dividend date is Friday, July 24th. Pfizer's dividend payout ratio is 131.30%.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.